Moleculin Biotech (MBRX) Common Equity (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Common Equity of $15.0 million for Q4 2025, up 33.89% year-over-year from $11.2 million in Q4 2024, and up 155.74% quarter-over-quarter from -$26.9 million in Q3 2025.
Moleculin Biotech (MBRX) Common Equity (2015 - 2026) Analysis & Trends
Moleculin Biotech's Common Equity history runs 11 years deep, the most recent figure standing at $15.0 million for Q4 2025.
- In Q4 2025, Common Equity rose 33.89% year-over-year to $15.0 million; the TTM figure through Dec 2025 stood at $15.0 million (up 33.89% YoY), while the FY2025 annual figure was $15.0 million, up 33.89% from the prior year.
- Common Equity for Q4 2025 stood at $15.0 million, up from -$26.9 million in the prior quarter.
- The five-year high for Common Equity was $88.5 million in Q1 2021, with the low at -$26.9 million in Q3 2025.
- The 5-year median for Common Equity is $37.7 million (2023), against an average of $40.3 million.
- The sharpest annual moves came in 2021 and 2025: Common Equity jumped 478.84% in 2021, then tumbled 254.61% in 2025.
- Moleculin Biotech's Common Equity stood at $79.0 million in 2021, then tumbled by 33.93% to $52.2 million in 2022, then plunged by 40.74% to $30.9 million in 2023, then sank by 63.76% to $11.2 million in 2024, then surged by 33.89% to $15.0 million in 2025.
- Business Quant data shows MBRX's Common Equity at $15.0 million in Q4 2025, -$26.9 million in Q3 2025, and -$3.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 9.79 Bn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | 11.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.59 Mn |
| Dec 31, 2025 | 15.01 Mn |
| Sep 30, 2025 | -26.92 Mn |
| Jun 30, 2025 | -3.59 Mn |
| Mar 31, 2025 | 13.79 Mn |
| Dec 31, 2024 | 11.21 Mn |
| Sep 30, 2024 | 17.41 Mn |
| Jun 30, 2024 | 19.41 Mn |
| Mar 31, 2024 | 24.99 Mn |
| Dec 31, 2023 | 30.93 Mn |
| Sep 30, 2023 | 35.14 Mn |
| Jun 30, 2023 | 40.27 Mn |
| Mar 31, 2023 | 45.68 Mn |
| Dec 31, 2022 | 52.19 Mn |
| Sep 30, 2022 | 58.42 Mn |
| Jun 30, 2022 | 66.36 Mn |
| Mar 31, 2022 | 72.67 Mn |
| Dec 31, 2021 | 78.99 Mn |
| Sep 30, 2021 | 81.26 Mn |
| Jun 30, 2021 | 84.70 Mn |